We are live on ! Find out more
SABS icon

SAB Biotherapeutics

34 hedge funds and large institutions have $25.4M invested in SAB Biotherapeutics in 2021 Q4 according to their latest regulatory filings, with 28 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 35 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 3

17% less funds holding

Funds holding: 41 → 34 (-7)

20% less first-time investments, than exits

New positions opened: 28 | Existing positions closed: 35

55.81% less ownership

Funds ownership: 62.93% → 7.12% (-56%)

73% less capital inflows, than outflows

Capital inflows: $23.1M | Capital outflows: $87.2M

Holders
34
Holders Change
-7
Holders Change %
-17.07%
% of All Funds
0.52%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
28
Increased
3
Reduced
3
Closed
35
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

SABS Hedge Fund Activity: Q4 2021 in Review

34 of the 6,524 institutional investors tracked by Wall St. Rank reported a position in SAB Biotherapeutics (SABS) for Q4 2021, worth a combined $25.4M — down 73% from $93.8M a quarter earlier.

Sellers outnumbered buyers: 35 funds closed out of SABS and 28 opened new positions — a net loss of 7 holders — while 3 trimmed existing stakes and 3 added.

The largest buyer was First PREMIER Bank, opening a new position worth an estimated $7.81M. The largest seller was Karpus Investment Management, exiting entirely with an estimated $10.4M sold.

  • 34 institutional investors held SAB Biotherapeutics (SABS) as of Q4 2021, down from 41 in Q3 2021.
  • Funds reported $25.4M of SAB Biotherapeutics stock for Q4 2021, down 73% quarter-over-quarter.
  • 28 funds opened new SAB Biotherapeutics positions in Q4 2021 and 35 closed out, a net change of -7 holders.
  • The largest SAB Biotherapeutics buyer in Q4 2021 was First PREMIER Bank, an estimated $7.81M added.
  • The largest SAB Biotherapeutics seller in Q4 2021 was Karpus Investment Management, an estimated $10.4M sold.

Based on aggregated 13F filings for Q4 2021.